866-997-4948(US-Canada Toll Free)

Diabetic Nephropathy Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Diabetes

No. of Pages : 132 Pages


Global Markets Directs, \'Diabetic Nephropathy Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Nephropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy. 

Diabetic Nephropathy Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Diabetic Nephropathy.
  • A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Diabetic Nephropathy pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diabetic Nephropathy Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Diabetic Nephropathy 9
Diabetic Nephropathy Therapeutics under Development by Companies 11
Diabetic Nephropathy Therapeutics under Investigation by Universities/Institutes 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Diabetic Nephropathy Therapeutics Products under Development by Companies 19
Diabetic Nephropathy Therapeutics Products under Investigation by Universities/Institutes 22
Companies Involved in Diabetic Nephropathy Therapeutics Development 23
Eli Lilly and Company 23
Questcor Pharmaceuticals, Inc. 24
Emergent BioSolutions Inc. 25
Otsuka Pharmaceutical Co., Ltd. 26
Astellas Pharma Inc. 27
Mitsubishi Tanabe Pharma Corporation 28
Pfizer Inc. 29
NephroGenex, Inc. 30
Torrent Pharmaceuticals Limited 31
Dongwha Pharm Co., Ltd. 32
PhytoHealth Corporation 33
Proximagen Neuroscience plc. 34
Angelini Group 35
IMMD Inc. 36
GenKyoTex S.A. 37
Thrasos, Inc. 38
Concert Pharmaceuticals, Inc. 39
NOXXON Pharma AG 40
ChemoCentryx, Inc. 41
Glucox Biotech 42
OncoImmune, Inc. 43
Centocor Ortho Biotech, Inc. 44
Cebix Incorporated 45
GENEXTRA S.p.A. 46
Ampio Pharmaceuticals, Inc. 47
Diabetic Nephropathy Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
baricitinib - Drug Profile 53
THR-123 - Drug Profile 55
NOX-A-12 - Drug Profile 56
NOX-E-36 - Drug Profile 58
IMD-1041 - Drug Profile 60
DT-22669 - Drug Profile 61
DT-23552 - Drug Profile 62
DW-1029M - Drug Profile 63
GKT-137831 - Drug Profile 64
PF-00489791 - Drug Profile 65
CCX-140 - Drug Profile 67
atrasentan hydrochloride - Drug Profile 69
LY-2382770 - Drug Profile 70
bindarit - Drug Profile 71
probucol - Drug Profile 73
Vasaloc - Drug Profile 74
colchicine - Drug Profile 75
PF-04634817 - Drug Profile 76
TRC-4149 - Drug Profile 77
GPCR Antagonist - Drug Profile 79
pyridoxamine dihydrochloride - Drug Profile 80
corticotropin zinc hydroxide - Drug Profile 82
CTP-499 - Drug Profile 83
A-717 - Drug Profile 85
MT-3995 - Drug Profile 86
GR-MD-02 - Drug Profile 87
Drug For Diabetic Nephropathy - Drug Profile 88
TNFR x TWEAKR - Drug Profile 89
cilostazol - Drug Profile 90
Drug For Diabetic Nephropathy - Drug Profile 91
VPI-2690B - Drug Profile 92
apocynin - Drug Profile 93
Program 2 Diabetic Nephropathy - Drug Profile 94
GKT-136901 - Drug Profile 95
NoX-1/4 Inhibitors - Drug Profile 97
Stem Cell Therapy For Diabetic Complications - Drug Profile 98
PHN-033 - Drug Profile 99
HPTPbeta mAb - Drug Profile 100
AKB-9089 - Drug Profile 101
Nox Enzymes Inhibitors - Drug Profile 102
Vascular Endothelial Growth Factor-165B - Drug Profile 103
ASP-8232 - Drug Profile 104
mPTP Inhibitors - Drug Profile 105
p66Shc Protein Inhibitors - Drug Profile 106
Diabetic Nephropathy Therapeutics Drug Profile Updates 107
Diabetic Nephropathy Therapeutics Discontinued Products 120
Diabetic Nephropathy Therapeutics - Dormant Products 121
Diabetic Nephropathy Product Development Milestones 122
Featured News & Press Releases 122

Appendix 128
Methodology 128
Coverage 128
Secondary Research 128
Primary Research 128
Expert Panel Validation 128
Contact Us 129
Disclaimer 129

List of Table


Number of Products Under Development for Diabetic Nephropathy, H1 2013 12
Products under Development for Diabetic Nephropathy Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Development by Companies, H1 2013 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2013 18
Comparative Analysis by Mid Clinical Stage Development, H1 2013 19
Comparative Analysis by Early Clinical Stage Development, H1 2013 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 21
Products under Development by Companies, H1 2013 22
Products under Development by Companies, H1 2013 (Contd..1) 23
Products under Development by Companies, H1 2013 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2013 25
Eli Lilly and Company, H1 2013 26
Questcor Pharmaceuticals, Inc., H1 2013 27
Emergent BioSolutions Inc., H1 2013 28
Otsuka Pharmaceutical Co., Ltd., H1 2013 29
Astellas Pharma Inc., H1 2013 30
Mitsubishi Tanabe Pharma Corporation, H1 2013 31
Pfizer Inc., H1 2013 32
NephroGenex, Inc., H1 2013 33
Torrent Pharmaceuticals Limited, H1 2013 34
Dongwha Pharm Co., Ltd., H1 2013 35
PhytoHealth Corporation, H1 2013 36
Proximagen Neuroscience plc., H1 2013 37
Angelini Group, H1 2013 38
IMMD Inc., H1 2013 39
GenKyoTex S.A., H1 2013 40
Thrasos, Inc., H1 2013 41
Concert Pharmaceuticals, Inc., H1 2013 42
NOXXON Pharma AG, H1 2013 43
ChemoCentryx, Inc., H1 2013 44
Glucox Biotech, H1 2013 45
OncoImmune, Inc., H1 2013 46
Centocor Ortho Biotech, Inc., H1 2013 47
Cebix Incorporated, H1 2013 48
GENEXTRA S.p.A., H1 2013 49
Ampio Pharmaceuticals, Inc., H1 2013 50
Assessment by Monotherapy Products, H1 2013 51
Assessment by Stage and Route of Administration, H1 2013 53
Assessment by Stage and Molecule Type, H1 2013 55
Diabetic Nephropathy Therapeutics Drug Profile Updates 110
Diabetic Nephropathy Therapeutics Discontinued Products 123
Diabetic Nephropathy Therapeutics Dormant Products 124

List of Chart


Number of Products under Development for Diabetic Nephropathy, H1 2013 12
Products under Development for Diabetic Nephropathy Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 18
Mid Clinical Stage Products, H1 2013 19
Early Clinical Stage Products, H1 2013 20
Discovery and Pre-Clinical Stage Products, H1 2013 21
Assessment by Monotherapy Products, H1 2013 51
Assessment by Route of Administration, H1 2013 52
Assessment by Stage and Route of Administration, H1 2013 53
Assessment by Molecule Type, H1 2013 54
Assessment by Stage and Molecule Type, H1 2013 55

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *